Ligand Pharmaceuticals Incorporated (LGND)

Ligand Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	115.08	174.93	72.31	22.95	45.01	19.52
Short-Term Investments	664.33	558.59	183.86	147.36	166.86	321.59
Cash & Short-Term Investments	779.41	733.52	256.17	170.31	211.87	341.11
Cash Growth	273.10%	186.35%	50.41%	-19.62%	-37.89%	-17.04%
Accounts Receivable	53.38	59.6	38.38	32.92	30.42	85.45
Inventory	13.27	9.13	14.11	23.97	13.29	27.33
Other Current Assets	19.36	30.02	22.9	10.23	8.01	10.86
Total Current Assets	865.42	832.27	331.56	237.43	263.6	464.75
Net Property, Plant & Equipment	-	-	-	25.06	27.49	32.6
Other Intangible Assets	217.34	225.44	266.65	299.61	342.46	376.69
Goodwill	101.54	101.54	105.25	103.37	105.67	105.67
Long-Term Investments	119.29	167.95	10.91	49.32	3	-
Other Long-Term Assets	228.52	233.44	227.41	72.43	20.45	317.87
Total Assets	1,532	1,561	941.77	787.22	762.67	1,298

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	5.26	3.24	5.23	2.43	5.31	8.4
Accrued Expenses	31.85	31.45	27.91	12.47	15.68	17.58
Current Portion of Long-Term Debt	-	-	-	-	76.7	-
Current Portion of Leases	1.09	1.1	1.27	0.41	0.72	1.41
Unearned Revenue	-	-	-	1.22	0.36	0.65
Other Current Liabilities	2.47	1.66	2.71	0.26	0.06	13.62
Total Current Liabilities	40.67	37.45	37.11	16.78	98.81	41.67
Long-Term Debt	446.9	446.19	-	-	-	320.72
Long-Term Leases	3.99	4.2	5.82	5.76	10.34	2.26
Other Long-Term Liabilities	43.23	55.58	68.41	63.77	56.04	111.79
Total Long-Term Liabilities	494.12	505.98	74.22	69.52	66.37	434.77
Total Liabilities	534.78	543.43	111.34	86.3	165.18	476.43

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Preferred Stock	-	-	-	-	-	0.02
Common Stock	0.02	0.02	0.02	0.02	0.02	0.02
Additional Paid-in Capital	397.17	400.65	337.38	198.7	147.59	372.97
Accumulated Other Comprehensive Income	5.39	8.46	-5.94	-0.82	-0.98	-0.92
Retained Earnings	594.74	608.09	498.98	503.02	450.86	449.09
Total Common Shareholders' Equity	997.32	1,017	830.44	700.91	597.49	821.18
Shareholders' Equity	997.32	1,017	830.44	700.91	597.49	821.16
Total Liabilities & Equity	1,532	1,561	941.77	787.22	762.67	1,298

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	451.98	451.49	7.08	6.17	87.75	324.39
Net Cash (Debt)	327.43	282.03	249.08	164.14	124.12	16.72
Net Cash Growth	60.15%	13.23%	51.75%	32.24%	642.28%	-
Net Cash Per Share	16.05	13.90	13.62	9.24	7.36	0.97
Book Value	997.32	1,017	830.44	700.91	597.49	821.18
Book Value Per Share	48.90	50.12	45.40	39.47	35.42	47.62
Tangible Book Value	678.44	690.23	458.54	297.94	149.36	338.81
Tangible Book Value Per Share	33.27	34.01	25.07	16.78	8.85	19.65

SEC Filings: 10-K · 10-Q

Data Source: Fiscal.ai Last updated: May 8, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 28, 2026

Data Sources Report a data error